BioCryst Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US09058V1035

Introduktion

Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for Robert Alexander Ingram. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.

Gennemsnitlig handelsrentabilitet

Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.

Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.

Opdateringsfrekvens: Dagligt

Se listen over de mest profitable insiderhandlere.

Virksomheder med rapporterede insider-stillinger

SEC-registreringen viser, at Robert Alexander Ingram har rapporteret besiddelser eller handler i følgende virksomheder:

Sikkerhed Titel Senest indberettede beholdninger
US:BCRX / BioCryst Pharmaceuticals, Inc. Director 100.198
US:BDTX / Black Diamond Therapeutics, Inc. 42.854
US:NOVN / Novan Inc Director 20.000
US:PHAS / PhaseBio Pharmaceuticals Inc 10% Owner 0
US:CREE / Cree, Inc. Director 77.710
US:GTHX / G1 Therapeutics, Inc. 10% Owner 3.237.711
US:BHC / Bausch Health Companies Inc. Director 92.046
US:CLSD / Clearside Biomedical, Inc. 10% Owner 2.060.514
US:REGN / Regeneron Pharmaceuticals, Inc. Director 1.500
US:EW / Edwards Lifesciences Corporation Director 32.367
Director 8.613
US:LOW / Lowe's Companies, Inc. Director 7.274
Sådan fortolkes diagrammerne

Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af Robert Alexander Ingram. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.

I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.

Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.

Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.

Insiderkøb BCRX / BioCryst Pharmaceuticals, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i BCRX / BioCryst Pharmaceuticals, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2019-11-18 BCRX INGRAM ROBERT ALEXANDER 20.000 1,4500 20.000 1,4500 29.000 184 5.61 83.200 286,90

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

BCRX / BioCryst Pharmaceuticals, Inc. Insider Trades
Insidersalg BCRX / BioCryst Pharmaceuticals, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i BCRX / BioCryst Pharmaceuticals, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

BCRX / BioCryst Pharmaceuticals, Inc. Insider Trades
Insiderkøb BDTX / Black Diamond Therapeutics, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i BCRX / BioCryst Pharmaceuticals, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2020-09-30 BDTX INGRAM ROBERT ALEXANDER 5.000 30,4570 5.000 30,4570 152.285 42 35.0000 22.715 14,92

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

BDTX / Black Diamond Therapeutics, Inc. Insider Trades
Insidersalg BDTX / Black Diamond Therapeutics, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i BCRX / BioCryst Pharmaceuticals, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

BDTX / Black Diamond Therapeutics, Inc. Insider Trades
Insiderkøb BHC / Bausch Health Companies Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i BCRX / BioCryst Pharmaceuticals, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

BHC / Bausch Health Companies Inc. Insider Trades
Insidersalg BHC / Bausch Health Companies Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i BCRX / BioCryst Pharmaceuticals, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

BHC / Bausch Health Companies Inc. Insider Trades
Insiderkøb CLSD / Clearside Biomedical, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i BCRX / BioCryst Pharmaceuticals, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2016-06-07 CLSD Hatteras Venture Advisors IV SBIC, LLC 414.286 7,0000 414.286 7,0000 2.900.002 126 24.7200 7.341.148 253,14
2016-06-07 CLSD Hatteras Venture Advisors III, LLC 107.142 7,0000 107.142 7,0000 749.994

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

CLSD / Clearside Biomedical, Inc. Insider Trades
Insidersalg CLSD / Clearside Biomedical, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i BCRX / BioCryst Pharmaceuticals, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2017-01-19 CLSD Hatteras Venture Advisors IV SBIC, LLC 7.592 8,2200 7.592 8,2200 62.406 334 5.7800 -18.524 -29,68
2017-01-19 CLSD Hatteras Venture Advisors III, LLC 6.478 8,2200 6.478 8,2200 53.249
2017-01-18 CLSD Hatteras Venture Advisors IV SBIC, LLC 12.258 8,6400 12.258 8,6400 105.909
2017-01-18 CLSD Hatteras Venture Advisors III, LLC 10.457 8,6400 10.457 8,6400 90.348
2017-01-17 CLSD Hatteras Venture Advisors IV SBIC, LLC 9.806 8,9200 9.806 8,9200 87.470
2017-01-17 CLSD Hatteras Venture Advisors III, LLC 8.366 8,9200 8.366 8,9200 74.625
2016-06-07 CLSD Hatteras Venture Advisors IV SBIC, LLC 69 7,0000 69 7,0000 483
2016-06-07 CLSD Hatteras Venture Advisors III, LLC 69 7,0000 69 7,0000 483

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

CLSD / Clearside Biomedical, Inc. Insider Trades
Insiderkøb WOLF / Wolfspeed, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i BCRX / BioCryst Pharmaceuticals, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2009-03-06 CREE INGRAM ROBERT ALEXANDER 1.000 18,9486 1.000 18,9486 18.949 360 69.71 50.762 267,90

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

WOLF / Wolfspeed, Inc. Insider Trades
Insidersalg WOLF / Wolfspeed, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i BCRX / BioCryst Pharmaceuticals, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2015-12-01 CREE INGRAM ROBERT ALEXANDER 3.750 27,6680 3.750 27,6680 103.755 338 21.1200 -24.555 -23,67

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

WOLF / Wolfspeed, Inc. Insider Trades
Insiderhandelshistorie

Denne tabel viser den komplette liste over insiderhandler foretaget af Robert Alexander Ingram som oplyst til Securities Exchange Commission (SEC).

Fil dato Transdato Form Ticker Sikkerhed Kode 10b5-1 Aktier Resterende aktier Procent
Lave om
Del
Pris
Tran
Værdi
Tilbage
Værdi
2023-03-02 2023-02-28 4 BCRX BIOCRYST PHARMACEUTICALS INC
Common Stock
A - Award 2.259 100.198 2,31 8,85 19.992 886.752
2022-12-19 2022-12-16 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
A - Award 9.375 42.854 28,00 1,50 14.062 64.281
2022-12-02 2022-11-30 4 BCRX BIOCRYST PHARMACEUTICALS INC
Common Stock
A - Award 1.497 97.939 1,55 13,36 20.000 1.308.465
2022-09-19 2022-09-16 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
A - Award 6.584 33.479 24,48 2,62 17.250 87.715
2022-09-02 2022-08-31 4 BCRX BIOCRYST PHARMACEUTICALS INC
Common Stock
A - Award 1.438 96.442 1,51 13,90 19.988 1.340.544
2022-06-17 2022-06-17 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
A - Award 8.498 26.895 46,19 2,03 17.251 54.597
2022-06-09 2022-06-07 4 BCRX BIOCRYST PHARMACEUTICALS INC
Common Stock
A - Award 12.866 95.004 15,66
2022-06-02 2022-05-31 4 BCRX BIOCRYST PHARMACEUTICALS INC
Common Stock
A - Award 2.078 82.138 2,60 9,31 19.346 764.705
2022-03-18 2022-03-18 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
A - Award 5.795 18.397 45,98 3,02 17.501 55.559
2022-03-02 2022-02-28 4 BCRX BIOCRYST PHARMACEUTICALS INC
Common Stock
A - Award 1.128 80.060 1,43 16,61 18.736 1.329.797
2021-12-17 2021-12-17 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
A - Award 3.296 12.602 35,42 5,31 17.502 66.917
2021-12-02 2021-11-30 4 BCRX BIOCRYST PHARMACEUTICALS INC
Common Stock
A - Award 1.554 78.932 2,01 12,06 18.741 951.920
2021-09-23 2021-09-17 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
A - Award 1.869 9.306 25,13 9,90 18.503 92.129
2021-09-02 2021-08-31 4 BCRX BIOCRYST PHARMACEUTICALS INC
Common Stock
A - Award 1.177 77.378 1,54 15,92 18.738 1.231.858
2021-06-22 2021-06-18 4 BDTX Black Diamond Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 15.000 15.000
2021-06-22 2021-06-18 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
A - Award 1.255 7.437 20,30 12,95 16.252 96.309
2021-06-01 2021-05-28 4 BCRX BIOCRYST PHARMACEUTICALS INC
Common Stock
A - Award 1.188 76.201 1,58 15,77 18.735 1.201.690
2021-05-27 2021-05-25 4 BCRX BIOCRYST PHARMACEUTICALS INC
Automatic Stock Option Grant
A - Award 40.000 40.000
2021-03-22 2021-03-18 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
A - Award 677 6.182 12,30 24,01 16.255 148.430
2021-03-02 2021-02-26 4 BCRX BIOCRYST PHARMACEUTICALS INC
Common Stock
A - Award 1.739 75.013 2,37 10,78 18.746 808.640
2020-12-16 2020-12-15 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
A - Award 505 5.505 10,10 34,29 17.316 188.766
2020-12-02 2020-11-30 4 BCRX BIOCRYST PHARMACEUTICALS INC
Common Stock
A - Award 3.669 73.274 5,27 5,11 18.749 374.430
2020-10-01 2020-09-30 4 BDTX Black Diamond Therapeutics, Inc.
Common Stock
P - Purchase 5.000 5.000 30,46 152.285 152.285
2020-09-29 2020-09-25 4 BDTX Black Diamond Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 29.842 29.842
2020-09-02 2020-08-31 4 BCRX BIOCRYST PHARMACEUTICALS INC
Common Stock
A - Award 4.518 69.605 6,94 4,15 18.750 288.861
2020-07-30 2020-07-28 4 NOVN Novan, Inc.
Stock Option (Right to Buy)
A - Award 20.000 20.000
2020-06-03 2020-06-01 4 BCRX BIOCRYST PHARMACEUTICALS INC
Common Stock
A - Award 4.171 65.087 6,85 4,50 18.749 292.566
2020-05-14 2020-05-12 4 BCRX BIOCRYST PHARMACEUTICALS INC
Automatic Stock Option Grant
A - Award 40.000 40.000
2020-03-03 2020-03-01 4 BCRX BIOCRYST PHARMACEUTICALS INC
Common Stock
A - Award 6.250 60.916 11,43 3,00 18.750 182.748
2019-12-03 2019-12-01 4 BCRX BIOCRYST PHARMACEUTICALS INC
Common Stock
A - Award 6.578 54.666 13,68 2,85 18.747 155.798
2019-11-18 2019-11-18 4 BCRX BIOCRYST PHARMACEUTICALS INC
Common Stock
P - Purchase 20.000 48.088 71,20 1,45 29.000 69.728
2019-09-04 2019-09-01 4 BCRX BIOCRYST PHARMACEUTICALS INC
Common Stock
A - Award 6.270 28.088 28,74 2,99 18.747 83.983
2019-08-02 2019-07-31 4 NOVN Novan, Inc.
Stock Option (Right to Buy)
A - Award 20.000 20.000
2019-05-31 2019-05-29 4 BCRX BIOCRYST PHARMACEUTICALS INC
Automatic Stock Option Grant
A - Award 30.000 30.000
2019-05-23 2019-05-22 4 NOVN Novan, Inc.
Common Stock
P - Purchase 50.000 169.777 41,74 2,21 110.500 375.207
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series D Preferred Stock
C - Conversion -226.061 0 -100,00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series D Preferred Stock
C - Conversion -24.709 0 -100,00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series D Preferred Stock
C - Conversion -272.107 0 -100,00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock
C - Conversion -40.420 0 -100,00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock
C - Conversion -13.558 0 -100,00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock
C - Conversion -149.320 0 -100,00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series B Preferred Stock
C - Conversion -94.874 0 -100,00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series B Preferred Stock
C - Conversion -1.044.764 0 -100,00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series AA Preferred Stock
C - Conversion -13.609 0 -100,00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series AA Preferred Stock
C - Conversion -174.699 0 -100,00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series 1 Preferred Stock
C - Conversion -4.846 0 -100,00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series 1 Preferred Stock
C - Conversion -3.862 0 -100,00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series 1 Preferred Stock
C - Conversion -42.530 0 -100,00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series 1 Preferred Stock
C - Conversion -52.690 0 -100,00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock
S - Sale -994 40.420 -2,40 5,00 -4.970 202.100
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock
X - Other 41.414 41.414 0,12 4.970 4.970
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Warrants to Purchase Series C-1 Preferred Stock
X - Other -41.414 0 -100,00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock
S - Sale -104 13.558 -0,76 5,00 -520 67.790
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock
X - Other 4.309 13.662 46,07 0,12 517 1.639
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Warrants to Purchase Series C-1 Preferred Stock
X - Other -4.309 0 -100,00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock
S - Sale -1.139 149.320 -0,76 5,00 -5.695 746.600
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock
X - Other 47.458 150.459 46,08 0,12 5.695 18.055
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Warrants to Purchase Series C-1 Preferred Stock
X - Other -47.458 0 -100,00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series B Preferred Stock
S - Sale -42 94.874 -0,04 5,00 -210 474.370
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series B Preferred Stock
X - Other 1.731 94.916 1,86 0,12 208 11.390
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Warrants to Purchase Series B Preferred Stock
X - Other -1.731 0 -100,00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series B Preferred Stock
S - Sale -458 1.044.764 -0,04 5,00 -2.290 5.223.820
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series B Preferred Stock
X - Other 19.061 1.045.222 1,86 0,12 2.287 125.427
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Warrants to Purchase Series B Preferred Stock
X - Other -19.061 0 -100,00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Common Stock
P - Purchase 150.000 416.481 56,29 5,00 750.000 2.082.405
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Common Stock
C - Conversion 266.481 266.481
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Common Stock
C - Conversion 4.846 4.846
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Common Stock
P - Purchase 12.487 163.099 8,29 5,00 62.435 815.495
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Common Stock
C - Conversion 150.612 150.612
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Common Stock
P - Purchase 137.513 1.820.933 8,17 5,00 687.565 9.104.665
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Common Stock
C - Conversion 1.683.420 1.683.420
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Common Stock
C - Conversion 52.690 52.690
2018-10-18 2018-10-17 4 CREE CREE INC
COMMON STOCK
A - Award 760 77.710 0,99 39,46 29.990 3.066.437
2018-10-01 2018-09-28 4 NOVN Novan, Inc.
Common Stock
P - Purchase 50.000 119.777 71,66 2,84 142.000 340.167
2018-08-31 2018-08-30 4 CREE CREE INC
NONQUALIFIED STOCK OPTION (RIGHT TO BUY)
M - Exercise -4.000 0 -100,00 30,92 -123.680
2018-08-31 2018-08-30 4 CREE CREE INC
COMMON STOCK
M - Exercise 4.000 76.950 5,48 30,92 123.680 2.379.294
2018-08-16 2018-08-15 4 CREE CREE INC
COMMON STOCK
A - Award 648 72.950 0,90 46,26 29.976 3.374.667
2018-06-22 2018-06-20 4 BCRX BIOCRYST PHARMACEUTICALS INC
Automatic Stock Option Grant
A - Award 30.000 30.000
2018-06-07 2018-06-04 4 NOVN Novan, Inc.
Stock Option (Right to Buy)
A - Award 20.000 20.000
2018-06-04 2018-06-01 4 BCRX BIOCRYST PHARMACEUTICALS INC
Common Stock
A - Award 2.916 21.818 15,43 6,43 18.750 140.290
2018-06-01 2018-05-30 4 GTHX G1 Therapeutics, Inc.
Common Stock
S - Sale -41.710 3.237.711 -1,27 48,00 -2.002.080 155.410.128
2018-06-01 2018-05-30 4 GTHX G1 Therapeutics, Inc.
Common Stock
S - Sale -758.290 3.279.421 -18,78 48,00 -36.397.920 157.412.208
2018-05-23 2018-05-23 4 GTHX G1 Therapeutics, Inc.
Common Stock
S - Sale -26 4.037.711 0,00 50,50 -1.313 203.904.406
2018-05-23 2018-05-23 4 GTHX G1 Therapeutics, Inc.
Common Stock
S - Sale -474 4.037.737 -0,01 50,50 -23.937 203.905.718
2018-05-23 2018-05-22 4 GTHX G1 Therapeutics, Inc.
Common Stock
S - Sale -308 4.038.211 -0,01 50,69 -15.611 204.677.128
2018-05-23 2018-05-22 4 GTHX G1 Therapeutics, Inc.
Common Stock
S - Sale -5.592 4.038.519 -0,14 50,86 -284.405 205.396.249
2018-05-23 2018-05-21 4 GTHX G1 Therapeutics, Inc.
Common Stock
S - Sale -26 4.044.111 0,00 52,13 -1.355 210.819.506
2018-05-23 2018-05-21 4 GTHX G1 Therapeutics, Inc.
Common Stock
S - Sale -474 4.044.137 -0,01 52,13 -24.710 210.820.862
2018-05-23 2018-05-21 4 GTHX G1 Therapeutics, Inc.
Common Stock
S - Sale -1.595 4.044.611 -0,04 51,06 -81.439 206.513.389
2018-05-23 2018-05-21 4 GTHX G1 Therapeutics, Inc.
Common Stock
S - Sale -29.005 4.046.206 -0,71 51,16 -1.483.907 207.005.517
2018-04-27 2018-04-25 4 CREE CREE INC
COMMON STOCK
A - Award 764 72.302 1,07 39,25 29.987 2.837.854
2018-03-02 2018-03-01 4 BCRX BIOCRYST PHARMACEUTICALS INC
Common Stock
A - Award 3.772 18.902 24,93 4,97 18.747 93.943
2018-01-26 2018-01-24 4 CREE CREE INC
COMMON STOCK
A - Award 833 71.538 1,18 35,98 29.971 2.573.937
2017-12-04 2017-12-01 4 BCRX BIOCRYST PHARMACEUTICALS INC
Common Stock
A - Award 3.690 15.130 32,26 5,08 18.745 76.860
2017-12-04 2017-11-30 4 GTHX G1 Therapeutics, Inc.
Common Stock
J - Other 995 4.075.211 0,02
2017-12-04 2017-11-30 4 GTHX G1 Therapeutics, Inc.
Common Stock
J - Other -99.513 4.074.216 -2,38
2017-10-20 2017-10-18 4 CREE CREE INC
COMMON STOCK
A - Award 731 70.705 1,04 34,16 24.971 2.415.283
2017-09-06 2017-09-01 4 CREE CREE INC
COMMON STOCK
A - Award 7.033 69.974 11,17
2017-09-05 2017-09-01 4 BCRX BIOCRYST PHARMACEUTICALS INC
Common Stock
A - Award 3.676 11.440 47,35 5,10 18.748 58.344
2017-08-29 2017-08-29 4 NOVN Novan, Inc.
Common Stock
P - Purchase 8.465 69.777 13,81 4,70 39.786 327.952
2017-08-29 2017-08-25 4 NOVN Novan, Inc.
Common Stock
P - Purchase 3.535 61.312 6,12 4,25 15.024 260.576
2017-08-24 2017-08-23 4 CREE CREE INC
COMMON STOCK
A - Award 1.125 62.941 1,82 22,21 24.986 1.397.920
2017-06-07 2017-06-05 4 NOVN Novan, Inc.
Stock Option (right to buy)
A - Award 34.014 34.014
2017-06-02 2017-06-01 4 BCRX BIOCRYST PHARMACEUTICALS INC
Common Stock
A - Award 1.941 7.764 33,33 5,15 9.996 39.985
2017-05-25 2017-05-24 4 BCRX BIOCRYST PHARMACEUTICALS INC
Automatic Stock Option Grant
A - Award 30.000 30.000
2017-05-24 2017-05-22 4 GTHX G1 Therapeutics, Inc.
Series C Preferred Stock
C - Conversion -1.009.693 0 -100,00
2017-05-24 2017-05-22 4 GTHX G1 Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -2.584.959 0 -100,00
2017-05-24 2017-05-22 4 GTHX G1 Therapeutics, Inc.
Series A Preferred Stock
C - Conversion -6.568.527 0 -100,00
2017-05-24 2017-05-22 4 GTHX G1 Therapeutics, Inc.
Series 1 Preferred Stock
C - Conversion -1.318.681 0 -100,00
2017-05-24 2017-05-22 4 GTHX G1 Therapeutics, Inc.
Common Stock
P - Purchase 133.333 3.861.797 3,58 15,00 1.999.995 57.926.955
2017-05-24 2017-05-22 4 GTHX G1 Therapeutics, Inc.
Common Stock
C - Conversion 99.513 99.513
2017-05-24 2017-05-22 4 GTHX G1 Therapeutics, Inc.
Common Stock
C - Conversion 212.419 212.419
2017-05-24 2017-05-22 4 GTHX G1 Therapeutics, Inc.
Common Stock
C - Conversion 3.728.464 3.728.464
2017-04-27 2017-04-26 4 CREE CREE INC
COMMON STOCK
A - Award 1.132 61.816 1,87 22,07 24.983 1.364.279
2017-04-04 2017-03-31 4 VRX Valeant Pharmaceuticals International, Inc.
Common Stock, no par value
A - Award 2.120 92.046 2,36 11,03 23.384 1.015.267
2017-03-02 2017-03-02 4 BCRX BIOCRYST PHARMACEUTICALS INC
Common Stock
A - Award 1.602 5.823 37,95 6,24 9.996 36.336
2017-01-26 2017-01-25 4 CREE CREE INC
COMMON STOCK
A - Award 867 60.684 1,45 28,83 24.996 1.749.520
2017-01-19 2017-01-19 4 CLSD Clearside Biomedical, Inc.
Common Stock
S - Sale -7.592 2.060.514 -0,37 8,22 -62.406 16.937.425
2017-01-19 2017-01-18 4 CLSD Clearside Biomedical, Inc.
Common Stock
S - Sale -12.258 2.068.106 -0,59 8,64 -105.909 17.868.436
2017-01-19 2017-01-17 4 CLSD Clearside Biomedical, Inc.
Common Stock
S - Sale -9.806 2.080.364 -0,47 8,92 -87.470 18.556.847
2017-01-19 2017-01-19 4 CLSD Clearside Biomedical, Inc.
Common Stock
S - Sale -6.478 1.757.719 -0,37 8,22 -53.249 14.448.450
2017-01-19 2017-01-18 4 CLSD Clearside Biomedical, Inc.
Common Stock
S - Sale -10.457 1.764.197 -0,59 8,64 -90.348 15.242.662
2017-01-19 2017-01-17 4 CLSD Clearside Biomedical, Inc.
Common Stock
S - Sale -8.366 1.774.654 -0,47 8,92 -74.625 15.829.914
2017-01-04 2016-12-30 4 VRX Valeant Pharmaceuticals International, Inc.
Common Stock, no par value
A - Award 1.463 89.926 1,65 14,52 21.243 1.305.726
2016-12-02 2016-12-01 4 BCRX BIOCRYST PHARMACEUTICALS INC
Common Stock
A - Award 1.788 4.221 73,49 5,59 9.995 23.595
2016-10-20 2016-10-19 4 CREE CREE INC
COMMON STOCK
A - Award 1.115 59.817 1,90 22,41 24.987 1.340.499
2016-10-05 2016-09-30 4 VRX Valeant Pharmaceuticals International, Inc.
Common Stock, no par value
A - Award 865 88.463 0,99 24,55 21.236 2.171.767
2016-09-28 2016-09-26 4 NOVN Novan, Inc.
Series 4 Preferred Stock
C - Conversion -27.777 0 -100,00
2016-09-28 2016-09-26 4 NOVN Novan, Inc.
Common Stock
C - Conversion 27.777 57.777 92,59
2016-09-22 2016-09-20 4 NOVN Novan, Inc.
Stock Option
A - Award 14.484 14.484
2016-09-20 3 NONE Novan, Inc.
Common Stock
60.000
2016-09-20 3 NONE Novan, Inc.
Common Stock
60.000
2016-09-06 2016-09-01 4 CREE CREE INC
COMMON STOCK
A - Award 6.429 58.702 12,30
2016-09-06 2016-09-01 4 BCRX BIOCRYST PHARMACEUTICALS INC
Common Stock
A - Award 2.433 2.433 4,11 10.000 10.000
2016-08-18 2016-08-17 4 CREE CREE INC
COMMON STOCK
A - Award 1.229 52.273 2,41 23,38 28.734 1.222.143
2016-07-11 2016-06-30 4 VRX Valeant Pharmaceuticals International, Inc.
Common Stock, no par value
A - Award 1.080 87.598 1,25 20,14 21.751 1.764.224
2016-06-21 2016-06-17 4 VRX Valeant Pharmaceuticals International, Inc.
Common Stock, no par value
A - Award 16.726 86.518 23,97
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Warrant to Purchase Common Stock (right to buy)
X - Other -21.705 0 -100,00
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Series C Preferred Stock
C - Conversion -337.897 0 -100,00
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Series B Preferred Stock
C - Conversion -432.941 0 -100,00
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Series A-1 Preferred Stock
C - Conversion -689.388 0 -100,00
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Series A Preferred Stock
C - Conversion -2.035.908 0 -100,00
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Common Stock
P - Purchase 414.286 2.090.170 24,72 7,00 2.900.002 14.631.190
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Common Stock
S - Sale -69 1.675.884 0,00 7,00 -483 11.731.188
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Common Stock
X - Other 21.705 1.675.953 1,31 0,02 478 36.871
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Common Stock
C - Conversion 1.598.223 1.654.248 2.852,70
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Warrant to Purchase Common Stock (right to buy)
X - Other -1.805 0 -100,00
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Warrant to Purchase Common Stock (right to buy)
X - Other -19.900 0 -100,00
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Series C Preferred Stock
C - Conversion -337.898 0 -100,00
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Series B Preferred Stock
C - Conversion -432.940 0 -100,00
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Series A-1 Preferred Stock
C - Conversion -689.388 0 -100,00
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Series A Preferred Stock
C - Conversion -2.035.907 0 -100,00
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Common Stock
P - Purchase 107.142 1.783.020 6,39 7,00 749.994 12.481.140
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Common Stock
S - Sale -69 1.675.878 0,00 7,00 -483 11.731.146
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Common Stock
X - Other 21.705 1.675.947 1,31 0,02 478 36.871
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Common Stock
C - Conversion 1.598.219 1.654.242 2.852,79
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
112.050
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
112.050
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
112.050
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
112.050
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
112.050
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
112.050
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
112.050
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
112.050
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
112.046
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
112.046
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
112.046
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
112.046
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
112.046
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
112.046
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
112.046
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
112.046
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
112.046
2016-05-25 2016-05-23 4 BCRX BIOCRYST PHARMACEUTICALS INC
Automatic Stock Option Grant
A - Award 30.000 30.000
2016-05-04 2016-05-02 4 VRX Valeant Pharmaceuticals International, Inc.
Common Stock, no par value
A - Award 926 69.792 1,34
2016-04-29 2016-04-27 4 CREE CREE INC
COMMON STOCK
A - Award 1.105 51.044 2,21 26,00 28.730 1.327.144
2016-01-22 2016-01-20 4 CREE CREE INC
COMMON STOCK
A - Award 1.093 49.939 2,24 26,30 28.746 1.313.396
2016-01-04 2015-12-31 4 VRX Valeant Pharmaceuticals International, Inc.
Common Stock, no par value
A - Award 239 68.866 0,35
2015-12-03 2015-12-01 4 CREE CREE INC
NONQUALIFIED STOCK OPTION (RIGHT TO BUY)
M - Exercise -3.750 0 -100,00
2015-12-03 2015-12-01 4 CREE CREE INC
COMMON STOCK
S - Sale -3.750 48.846 -7,13 27,67 -103.755 1.351.471
2015-12-03 2015-12-01 4 CREE CREE INC
COMMON STOCK
M - Exercise 3.750 52.596 7,68 14,71 55.162 773.687
2015-10-23 2015-10-21 4 CREE CREE INC
COMMON STOCK
A - Award 1.199 48.846 2,52 23,96 28.728 1.170.350
2015-10-02 2015-09-30 4 VRX Valeant Pharmaceuticals International, Inc.
Common Stock, no par value
A - Award 136 68.627 0,20
2015-09-03 2015-09-01 4 CREE CREE INC
COMMON STOCK
A - Award 6.674 47.647 16,29
2015-08-14 2015-08-12 4 CREE CREE INC
COMMON STOCK
A - Award 1.112 40.973 2,79 26,58 29.557 1.089.062
2015-08-07 2015-08-05 4 BCRX BIOCRYST PHARMACEUTICALS INC
Non-Qualified Stock Option
A - Award 18.750 18.750
2015-07-02 2015-06-30 4 VRX Valeant Pharmaceuticals International, Inc.
Common Stock, no par value
A - Award 109 68.491 0,16
2015-05-27 2015-05-22 4 VRX Valeant Pharmaceuticals International, Inc.
Common Stock, no par value
A - Award 1.607 68.382 2,41
2015-05-27 2015-05-27 4 REGN REGENERON PHARMACEUTICALS INC
Common Stock
S - Sale -1.379 1.500 -47,90 513,39 -707.965 770.085
2015-05-27 2015-05-22 4 REGN REGENERON PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy)
M - Exercise -6.667 13.333 -33,34
2015-05-27 2015-05-22 4 REGN REGENERON PHARMACEUTICALS INC
Common Stock
F - Taxes -3.788 2.879 -56,82 516,48 -1.956.426 1.486.946
2015-05-27 2015-05-22 4 REGN REGENERON PHARMACEUTICALS INC
Common Stock
M - Exercise 6.667 6.667 293,53 1.956.965 1.956.965
2015-05-19 2015-05-15 4 EW Edwards Lifesciences Corp
Common Stock
A - Award 305 32.367 0,95
2015-05-19 2015-05-15 4 EW Edwards Lifesciences Corp
Common Stock
A - Award 1.521 32.062 4,98
2015-04-24 2015-04-22 4 CREE CREE INC
COMMON STOCK
A - Award 811 39.861 2,08 32,36 26.244 1.289.902
2015-04-02 2015-03-31 4 VRX Valeant Pharmaceuticals International, Inc.
Common Stock, no par value
A - Award 122 66.775 0,18
2015-01-23 2015-01-21 4 CREE CREE INC
COMMON STOCK
A - Award 775 39.050 2,02 33,87 26.249 1.322.624
2015-01-05 2015-01-02 4 REGN REGENERON PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy)
A - Award 10.838 10.838
2014-10-24 2014-10-22 4 CREE CREE INC
COMMON STOCK
A - Award 962 38.275 2,58 27,27 26.234 1.043.759
2014-09-04 2014-09-02 4 CREE CREE INC
COMMON STOCK
A - Award 4.244 37.313 12,83
2014-08-15 2014-08-13 4 CREE CREE INC
COMMON STOCK
A - Award 390 33.069 1,19 44,81 17.476 1.481.822
2014-08-01 2014-07-31 4 EW Edwards Lifesciences Corp
Common Stock
S - Sale -12.500 30.541 -29,04 90,26 -1.128.279 2.756.701
2014-05-28 2014-05-23 4 VRX Valeant Pharmaceuticals International, Inc.
Common Shares, no par value
A - Award 2.866 66.653 4,49
2014-05-13 2014-05-09 4 EW Edwards Lifesciences Corp
Common Stock
A - Award 469 43.041 1,10
2014-05-13 2014-05-09 4 EW Edwards Lifesciences Corp
Common Stock
A - Award 2.342 42.572 5,82
2014-04-25 2014-04-23 4 CREE CREE INC
COMMON STOCK
A - Award 343 32.679 1,06 51,01 17.496 1.666.956
2014-04-08 2014-04-04 4 REGN REGENERON PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy)
A - Award 20.000 20.000
2014-01-24 2014-01-22 4 CREE CREE INC
COMMON STOCK
A - Award 222 32.336 0,69 67,30 14.941 2.176.213
2013-10-25 2013-10-23 4 CREE CREE INC
COMMON STOCK
A - Award 242 32.114 0,76 61,75 14.944 1.983.040
2013-09-04 2013-09-03 4 CREE CREE INC
NONQUALIFIED STOCK OPTION (RIGHT TO BUY)
A - Award 4.000 4.000
2013-09-04 2013-09-03 4 CREE CREE INC
COMMON STOCK
A - Award 4.000 31.872 14,35
2013-08-16 2013-08-14 4 CREE CREE INC
COMMON STOCK
A - Award 255 27.872 0,92 58,82 14.999 1.639.431
2013-06-06 2013-06-04 4 VRX Valeant Pharmaceuticals International, Inc.
Common Shares, no par value
F - Taxes -1.279 63.787 -1,97 88,21 -112.821 5.626.651
2013-06-03 2013-05-30 4 VRX Valeant Pharmaceuticals International, Inc.
Deferred Share Units
D - Sale to Issuer -1.319 1.281 -50,73 90,81 -119.778 116.328
2013-06-03 2013-05-30 4 VRX Valeant Pharmaceuticals International, Inc.
Common Stock, no par value
D - Sale to Issuer -127.128 65.066 -66,15 90,81 -11.544.494 5.908.643
2013-05-28 2013-05-24 4 vrx Valeant Pharmaceuticals International, Inc.
Common Shares, no par value
A - Award 5.022 192.194 2,68
2013-05-17 2013-05-15 4 EW Edwards Lifesciences Corp
Common Stock
A - Award 563 40.230 1,42
2013-05-17 2013-05-15 4 EW Edwards Lifesciences Corp
Common Stock
A - Award 2.811 39.667 7,63
2013-04-26 2013-04-24 4 CREE CREE INC
COMMON STOCK
A - Award 265 27.617 0,97 56,46 14.962 1.559.256
2013-01-25 2013-01-23 4 CREE CREE INC
COMMON STOCK
A - Award 367 27.352 1,36 40,85 14.992 1.117.329
2012-10-31 2012-10-29 4 AGN ALLERGAN INC
Phantom Stock Units
A - Award 22 8.613 0,25 91,64 2.000 789.293
2012-10-19 2012-10-17 4 CREE CREE INC
COMMON STOCK
A - Award 518 26.985 1,96 28,92 14.981 780.406
2012-10-02 2012-10-01 4 AGN ALLERGAN INC
Phantom Stock Units
A - Award 27 8.591 0,32 92,63 2.500 795.798
2012-10-02 2012-10-01 4 AGN ALLERGAN INC
Phantom Stock Units
A - Award 162 8.564 1,93 92,63 15.000 793.298
2012-09-26 2012-09-24 4 AGN ALLERGAN INC
Phantom Stock Units
A - Award 16 8.402 0,19 91,75 1.500 770.905
2012-09-26 2012-09-24 4 AGN ALLERGAN INC
Phantom Stock Units
A - Award 16 8.402 0,19 91,75 1.500 770.905
2012-09-26 2012-09-24 4 AGN ALLERGAN INC
Phantom Stock Units
A - Award 22 8.370 0,26 91,75 2.000 767.904
2012-09-26 2012-09-13 4 AGN ALLERGAN INC
Phantom Stock Units
A - Award 5 8.348 0,06 89,31 417 745.536
2012-09-06 2012-09-04 4 CREE CREE INC
NONQUALIFIED STOCK OPTION (RIGHT TO BUY)
A - Award 4.000 4.000
2012-09-06 2012-09-04 4 CREE CREE INC
COMMON STOCK
A - Award 4.000 26.467 17,80
2012-08-10 2012-08-08 4 CREE CREE INC
COMMON STOCK
A - Award 553 22.467 2,52 27,11 14.992 609.080
2012-08-01 2012-07-31 4 AGN ALLERGAN INC
Phantom Stock Units
A - Award 24 8.343 0,29 82,07 2.000 684.715
2012-08-01 2012-07-30 4 AGN ALLERGAN INC
Phantom Stock Units
A - Award 18 8.319 0,21 85,30 1.500 709.584
2012-08-01 2012-07-30 4 AGN ALLERGAN INC
Phantom Stock Units
A - Award 18 8.319 0,21 85,30 1.500 709.584
2012-07-03 2012-07-02 4 AGN ALLERGAN INC
Phantom Stock Units
A - Award 26 8.284 0,32 94,77 2.500 785.030
2012-07-03 2012-07-02 4 AGN ALLERGAN INC
Phantom Stock Units
A - Award 158 8.257 1,95 94,77 15.000 782.530
2012-07-03 2012-06-14 4 AGN ALLERGAN INC
Phantom Stock Units
A - Award 4 8.099 0,05 91,64 405 742.180
2012-06-04 2012-06-04 4 VRX Valeant Pharmaceuticals International, Inc.
Common Shares, no par value
A - Award 8.062 187.172 4,50
2012-06-01 2012-05-30 4 VRX Valeant Pharmaceuticals International, Inc.
Common Stock, no par value
D - Sale to Issuer -44.634 179.110 -19,95
2012-05-25 2012-05-25 4 EW Edwards Lifesciences Corp
Common Stock
S - Sale -15.000 36.856 -28,93 87,72 -1.315.800 3.233.008
2012-05-14 2012-05-11 4 EW Edwards Lifesciences Corp
Common Stock
A - Award 473 51.856 0,92
2012-05-14 2012-05-11 4 EW Edwards Lifesciences Corp
Common Stock
A - Award 2.361 51.383 4,82
2012-05-02 2012-05-01 4 AGN ALLERGAN INC
Phantom Stock Units
A - Award 21 8.094 0,26 96,39 2.000 780.224
2012-05-02 2012-05-01 4 AGN ALLERGAN INC
Common Stock
A - Award 4.800 19.382 32,92
2012-05-02 2012-04-30 4 AGN ALLERGAN INC
Phantom Stock Units
A - Award 16 8.074 0,19 96,00 1.500 775.075
2012-05-02 2012-04-30 4 AGN ALLERGAN INC
Phantom Stock Units
A - Award 16 8.074 0,19 96,00 1.500 775.075
2012-04-20 2012-04-18 4 CREE CREE INC
COMMON STOCK
A - Award 500 21.914 2,33 29,97 14.985 656.763
2012-04-03 2012-04-02 4 AGN ALLERGAN INC
Phantom Stock Units
A - Award 26 8.042 0,33 95,17 2.500 765.399
2012-04-03 2012-04-02 4 AGN ALLERGAN INC
Phantom Stock Units
A - Award 158 8.016 2,01 95,17 15.000 762.899
2012-04-03 2012-03-16 4 AGN ALLERGAN INC
Phantom Stock Units
A - Award 4 7.859 0,05 93,00 392 730.846
2012-02-01 2012-01-31 4 AGN ALLERGAN INC
Phantom Stock Units
A - Award 23 7.854 0,29 87,91 2.000 690.475
2012-02-01 2012-01-30 4 AGN ALLERGAN INC
Phantom Stock Units
A - Award 17 7.832 0,22 88,06 1.500 689.650
2012-02-01 2012-01-30 4 AGN ALLERGAN INC
Phantom Stock Units
A - Award 17 7.832 0,22 88,06 1.500 689.650
2012-01-20 2012-01-18 4 CREE CREE INC
COMMON STOCK
A - Award 613 21.414 2,95 24,44 14.982 523.358
2012-01-05 2012-01-03 4 AGN ALLERGAN INC
Phantom Stock Units
A - Award 28 7.798 0,36 88,42 2.500 689.458
2012-01-05 2012-01-03 4 AGN ALLERGAN INC
Phantom Stock Units
A - Award 170 7.769 2,23 88,42 15.000 686.958
2012-01-04 2011-12-31 4 VRX Valeant Pharmaceuticals International, Inc.
Common Stock, no par value
A - Award 220 223.744 0,10
2011-10-21 2011-10-19 4 CREE CREE INC
COMMON STOCK
A - Award 514 20.801 2,53 24,30 12.490 505.464
2011-10-03 2011-09-30 4 VRX Valeant Pharmaceuticals International, Inc.
Common Stock, no par value
A - Award 277 220.690 0,13
2011-09-02 2011-09-01 4 CREE CREE INC
NONQUALIFIED STOCK OPTION (RIGHT TO BUY)
A - Award 4.000 4.000
2011-09-02 2011-09-01 4 CREE CREE INC
COMMON STOCK
A - Award 4.000 20.287 24,56
2011-08-11 2011-08-10 4 CREE CREE INC
COMMON STOCK
A - Award 367 16.287 2,31 34,03 12.489 554.247
2011-04-21 2011-04-20 4 CREE CREE INC
COMMON STOCK
A - Award 315 15.920 2,02 39,67 12.496 631.546
2011-01-21 2011-01-19 4 CREE CREE INC
COMMON STOCK
A - Award 233 15.605 1,52 53,57 12.482 835.960
2010-10-22 2010-10-20 4 CREE CREE INC
COMMON STOCK
A - Award 249 15.372 1,65 50,02 12.455 768.907
2010-08-13 2010-08-11 4 CREE CREE INC
COMMON STOCK
A - Award 209 10.123 2,11 59,78 12.494 605.153
2010-05-18 2010-05-14 4 EW Edwards Lifesciences Corp
Common Stock
A - Award 199 30.651 0,65
2010-05-18 2010-05-14 4 EW Edwards Lifesciences Corp
Common Stock
A - Award 1.987 30.452 6,98
2010-04-23 2010-04-21 4 CREE CREE INC
COMMON STOCK
A - Award 164 9.914 1,68 76,19 12.495 755.348
2009-03-10 2009-03-06 4 CREE CREE INC
COMMON STOCK
P - Purchase 1.000 4.750 26,67 18,95 18.949 90.006
2008-12-31 2008-12-29 4 CREE CREE INC
NONQUALIFIED STOCK OPTION (RIGHT TO BUY)
A - Award 3.750 3.750
2008-12-31 2008-12-29 4 CREE CREE INC
COMMON STOCK
A - Award 3.750 3.750
2006-01-03 2005-12-31 4 LOW LOWES COMPANIES INC
Phantom Stock
A - Award 281 7.274 4,02 66,66 18.750 484.886
2004-06-01 2004-05-28 4 LOW LOWES COMPANIES INC
Non-Qualified Stock Option (right to buy)
A - Award 4.000 4.000
2004-05-17 2004-05-13 4 EW EDWARDS LIFESCIENCES CORP
Common Stock
A - Award 4.000 9.000 80,00
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)